HPV vaccination is beneficial and effective after age 26
While HPV vaccination can still be immunogenic and provide individual benefits for some adults over age 26, its broader population-level effectiveness and cost-effectiveness are debated and generally not recommended for routine use.
The retrieved literature acknowledges that HPV vaccines remain immunogenic and can offer individual protection to adults over 26 who have ongoing exposure risks (Papers [0], [11]). However, health economic and cost-effectiveness evaluations demonstrate that routine expansion to older adults yields very high cost-per-QALY ratios and is generally not considered cost-effective at a population level (Papers [1], [3]). This creates a split between individual-level immunologic benefit/efficacy and population-level cost-effectiveness recommendations, justifying a CONTESTED verdict.
The evidence we hold leans evenly split
How this was weighed
official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x
- Human Papillomavirus Vaccine Efficacy and Effectiveness agai · peer-reviewed · supports · weight 2 · 2021
- Human Papillomavirus Vaccination Beyond Age 26: Evidence, Li · peer-reviewed · supports · weight 1 · 2026
- Human papillomavirus vaccination for adults aged 30 to 45 ye · peer-reviewed · refutes · weight 1.3 · 2021
- Cost-effectiveness of HPV vaccination for adults through age · peer-reviewed · refutes · weight 1.3 · 2020
S. Kamolratanakul, P. Pitisuttithum. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. 2021. https://doi.org/10.3390/vaccines9121413
Paper [0] notes that adults aged 27-45 who are at risk of new HPV infection might benefit from vaccination.
Jane J. Kim, K. Simms, J. Killen, Megan A. Smith, E. Burger, S. Sy, C. Regan, K. Canfell. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. 2021. https://doi.org/10.1371/journal.pmed.1003534
Paper [1] concludes that HPV vaccination for adults aged 30 to 45 is unlikely to represent good value for money in the US due to high ICERs.
See more details
Lebbos J, Kassis P, Navas C, Nahle R, Choucair J, Azzi A. Human Papillomavirus Vaccination Beyond Age 26: Evidence, Limitations, And Implications For Vaccination Policy.. 2026. https://doi.org/10.1177/21501319261454570
Paper [11] indicates that HPV vaccines remain immunogenic and safe in adults over 26, providing individual benefit for those with ongoing exposure risks.
H. Chesson, E. Meites, D. Ekwueme, M. Saraiya, L. Markowitz. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. 2020. https://doi.org/10.1016/j.vaccine.2020.10.019
Paper [3] finds that mid-adult vaccination is much less cost-effective compared to routine adolescent and catch-up programs.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt